Back to Authors

Farrow, George M.

Mayo Clinic

Mayo Clinic

Citations 56

13- cis -Retinoic Acid: Inhibition of Bladder Carcinogenesis Induced in Rats by N -Butyl- N -(4-hydroxybutyl)nitrosamine
Grubbs, Clinton J., Moon, Richard C., Squire, Robert A., Farrow, George M., Stinson, Sherman F., Goodman, Dawn G., Brown, Charles, Sporn, Michael B.

Science | October 5, 2006 | Volume: 198 | Issue: 4318 | Pages: 743-744

10.1126/science.910158 Get It

Transitional cell carcinoma was induced in the bladders of male Fischer rats by 12 oral doses of the carcinogen N -butyl- N -(4-hydroxybutyl)nitrosamine. Feeding of 13-cis-retinoic acid after completion of carcinogen treatment diminished the number and severity of cancers and other proliferative lesions of the bladder.
Prospective Analysis of Computerized Tomography and Needle Biopsy With Permanent Sectioning to Determine the Nature of Solid Renal Masses in Adults
Dechet, Christopher , Zincke, Horst, Sebo, Thomas J., King, Bernard F., LeRoy, Andrew J., Farrow, George M., Blute, Michael L.

Journal of Urology | January 18, 2006 | Volume: 169 | Issue: 1 | Pages: 71-74

10.1016/s0022-5347(05)64038-4 Get It

Renal Oncocytoma: A Reappraisal of Morphologic Features With Clinicopathologic Findings in 80 Cases
Amin, Mahul B. , Crotty, Thomas B., Tickoo, Satish K. , Farrow, George M.

Journal of Urology | January 17, 2006 | Volume: 161 | Issue: 5 | Pages: 1735-1736

10.1016/s0022-5347(05)69050-7 Get It

PROSPECTIVE ANALYSIS OF INTRAOPERATIVE FROZEN NEEDLE BIOPSY OF SOLID RENAL MASSES IN ADULTS
Dechet, Christopher , Sebo, Thomas J., Farrow, George M., Blute, Michael L., Engen, Donald E., Zincke, Horst

Journal of Urology | January 17, 2006 | Volume: 162 | Issue: 4 | Pages: 1282-1284

10.1016/s0022-5347(05)68265-1 Get It

Chromophobe Cell Renal Carcinoma: Clinicopathological Features of 50 Cases
Crotty, Thomas B., Farrow, George M., Lieber, Michael M.

Journal of Urology | January 17, 2006 | Volume: 154 | Issue: 3 | Pages: 964-967

10.1016/s0022-5347(01)66944-1 Get It

Flow cytometric DNA measurements in benign and malignant Hürthle cell tumors of the thyroid
Ryan, John J., Grant, Clive S., Rainwater, Leslie M., Farrow, George M., Goellner, John R., Hay, Ian

World Journal of Surgery | May 8, 2005 | Volume: 12 | Issue: 4 | Pages: 482-487

10.1007/bf01655427 Get It

AbstractThe prediction of outcome in the rare Hürthle cell tumor of the thyroid continues to present a problem to surgeons and pathologists. To better clarify the distinctions between benign and malignant tumors, we have measured DNA content by flow cytometry on isolated cell nuclei derived from archival paraffin‐embedded tissue blocks of 125 Hürthle cell tumors operated from 1943 to 1985 at the Mayo Clinic, Rochester, Minnesota, U.S.A. Nuclear DNA ploidy patterns were divided into 3 groups. A DNA normal (diploid) pattern was found in 55% of 75 Hürthle cell adenomas and in 26% of 50 Hürthle cell cancers; a DNA tetraploid/polyploid pattern was found in 11% of benign, and 14% of malignant tumors. An abnormal DNA stemline was detected in 34% of benign and 60% of malignant tumors. Hürthle cell cancer was the histologic diagnosis in 24% of the DNA normal, 47% of the DNA tetraploid/polyploid, and 54% of the DNA aneuploid tumors. None of the patients with adenomas developed tumor recurrence. However, 20% of the euploid and 40% of the aneuploid tumors developed local or distant recurrences. Survival to thyroid cancer death was significantly correlated with DNA ploidy status (p=0.02) but did not correlate with either tumor size or histologic grade. To date, deaths from thyroid cancer have been confined to patients whose tumors were DNA aneuploid. We would conclude that determination of DNA ploidy status may not aid the surgical pathologist in the diagnosis of Hürthle cell cancer. However, when a patient's Hürthle cell cancer is DNA aneuploid, there is significant risk of death from thyroid cancer.